GoldenGolden
Histogen

Histogen

Histogen is a biotechnology company developing regenerative medicines using stem cells to stimulate hair growth.

Histogen is a clinical-stage therapeutics company that focuses on developing potential restorative therapeutics that ignite the natural process of the body to repair and maintain healthy biological function. The innovative technology platform of Histogen uses cell-conditioned media and extracellular matrix materials that are produced by hypoxia-induced multipotent cells.

The company focused on developing innovative products based upon Histogen’s unique technology that utilizes the proteins and growth factors produced by cells grown under simulated embryonic conditions.

Histogen’s proprietary, reproducible manufacturing process delivers targeted solutions to a wide range of therapeutic indications that include dermal rejuvenation, hair growth, joint cartilage regeneration and spinal disk repair.

The company's mission is to redefine regenerative medicine by developing high value therapeutic and aesthetic products that stimulate the body’s own stem cells to regenerate tissues, without the use of embryonic stem cells or animal components.

Timeline

May 28, 2020
Histogen announces the appointment of Susan A. Knudson as Executive Vice President and Chief Financial Officer.
2007
Histogen was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Hair regrowth treatment now being tested in women by La Jolla's Histogen

Bradley J. Fikes

Web

HISTOGEN PHASE 3 TRIALS ON MEN BEGIN IN MEXICO

Hair Loss Cure 2020

Web

Histogen’s Growth Factor Technology to be Marketed as Part of Allergan Skin Care Line

Business Wire

Web

Documentaries, videos and podcasts

Title
Date
Link

Can Histogen Regrow Hair? | Thinning Hair

October 6, 2012

Histogen - Company Presentation

October 22, 2014

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
December 1, 2020
BioSpace
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated w ith No Serious Adverse Events Week 26 Final Study Results for HST-001 Expected in Early First Quarter of 2021
BioSpace
June 1, 2020
BioSpace
Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company's lead therapeutic candidate for the treatment of androgenic alopecia in men. This blinded, randomized, placebo controlled, single site study will enroll 36 subjects with male pattern hair loss u
BioSpace
May 28, 2020
BioSpace
Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the appointment of Susan A. Knudson as Executive Vice President and Chief Financial Officer.
BioSpace
May 14, 2020
BioSpace
Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. The ma

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.